


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A tetrahydroquinoline derivative according to Formula 1,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are H or Me

R<sup>3</sup> is H, hydroxy, (1-4C)alkoxy,

R<sup>4</sup> is H, OH, or (1-4C)alkoxy,

R<sup>5</sup> is OH, (1-4C)alkoxy or R<sup>7</sup>,

with the proviso that if R<sup>4</sup> is H, R<sup>5</sup> is not OH or (1-4C)alkoxy

R<sup>6</sup> is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, or (1-6C)alkyl,

wherein the (2-5C)heteroaryl and the (6C)aryl are optionally substituted with one or more substituents selected from hydroxyl, amino, halogen, phenyl, (1-4C)alkyl, (1-4C)alkoxy, or (1-4C)(di)alkylamino,

R<sup>7</sup> is amino, (di)(1-4C)alkylamino, (2-5C)heteroarylcarbonylamino, (2-5C)heteroarylcarbonyloxy, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy

R<sup>8</sup> is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl, (2-6C)heterocycloalkylcarbonylamino, or (1-4C)alkoxycarbonylamino and

$R^9$  is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl, optionally substituted with one or more (1-4C)alkyl substituents, or (6C)aryl.

2. (Cancelled).

3. (Cancelled).

4. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein  $R^8$  is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.

5. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein  $R^7$  is (di)(1-4C)alkylamino,  $R^8$ -(2-4C)alkoxy,  $R^9$ -methylamino or  $R^9$ -methoxy.

6. (Previously presented) The tetrahydroquinoline derivative of claim 5 wherein  $R^8$  is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.

7. (Previously presented) The tetrahydroquinoline derivative of claim 6 wherein  $R^8$  is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.

8. (Cancelled).

9. (Previously Presented) The tetrahydroquinoline derivative of claim 5 wherein  $R^6$  is (2-5C)heteroaryl or (6C)aryl.

10. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein  $R^6$  is (4-5C)heteroaryl or (6C)aryl and  $R^9$  is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

11. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein  $R^7$  is (di)(1-4C)alkylamino,  $R^8$ -ethoxy,  $R^9$ -methylamino or  $R^9$ -methoxy and  $R^9$  is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

12. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>8</sup> is (di)(1-4C)alkylamino or (4-5C)heterocycloalkyl and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

13. (Previously presented) A pharmaceutical composition comprising the tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.

14. (Cancelled)

15. (Cancelled)

16. (Currently Amended) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 13 to a patient in need thereof, wherein the fertility regulation is contraception in a female.